top of page
Baricitinib
Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2. Previous studies have shown that baricitinib significantly reduced the concentration of anti-dsDNA antibodies and downregulated the expression of key cytokines associated with SLE pathogenesis via the JAK and signal transducer and activator of transcription (STAT; JAK–STAT) pathway.
Enroll in this clinical study
How is Baricitenib being studied in Lupus nephritis?
The efficacy and safety of Baricitinib in patients with LN by dose 4 mg versus 2 mg versus MMF 1 gm daily dose to maintain Lupus Remission is being studied in this randomized controlled trial. The primary outcome is the urine protein creatinine ratio at 3,6 and 12 months.
Eligibility Criteria
Aged 20-70 years
Clinical diagnosis of Lupus nephritis Disease
Lupus nephritis in remission
bottom of page